Minimal Residual Disease Testing Market Trends And Growth Drivers Point To Strong Future Potential
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Minimal Residual Disease Testing Market Size And Revenue Forecast Through 2030
The market for minimal residual disease testing has experienced swift expansion in recent times. Its value is projected to increase from $1.8 billion in 2025 to $2.02 billion by 2026, reflecting a compound annual growth rate (CAGR) of 12.5%. This historical growth has been fueled by factors such as the rising incidence of hematological cancers, breakthroughs in molecular diagnostics, heightened awareness concerning residual disease, a growing embrace of personalized treatment approaches, and backing from government healthcare programs.
The minimal residual disease testing market is projected to experience significant expansion in the coming years. By 2030, its value is anticipated to reach $3.31 billion, reflecting a compound annual growth rate (CAGR) of 13.1%. This forecasted growth is driven by several factors, including progress in next-generation sequencing and digital PCR technologies, increased funding for cancer research, stronger partnerships between diagnostic firms and pharmaceutical companies, a growing need for tailored treatment monitoring, and improvements to healthcare infrastructure in emerging economies. Key trends shaping this period involve the adoption of liquid biopsies, customized cancer surveillance, enhanced early detection and prognosis capabilities, the incorporation of molecular diagnostics, and a broader focus on oncology research.
Download A Free Sample Report For Comprehensive Market Insights:
Minimal Residual Disease Testing Market Industry Drivers: What Is Driving Revenue Growth?
The anticipated rise in cancer incidence is set to drive the expansion of the minimal residual disease testing market in the coming period. This condition involves the uncontrolled growth of certain cells within the body, which can then spread to other areas. Through minimal residual disease testing, a highly sensitive technique, cancer stages can be identified by detecting cancerous cells present in the human body, enabling early intervention for patients and thereby supporting market growth. For example, data from the National Institutes of Health (NIH), a U.S. government agency, indicated in January 2023 that 1,958,310 new cancer cases and 609,820 cancer deaths were recorded in the United States that year. Consequently, the growing prevalence of cancer is fueling the momentum of the minimal residual disease testing market.
Minimal Residual Disease Testing Market Categorization By Product Type And Application
The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry
Minimal Residual Disease Testing Market Growth Trends: What Is Influencing The Future Outlook?
In the minimal residual disease testing market, leading firms are introducing advanced cancer research testing solutions designed to improve detection sensitivity, refine treatment monitoring, and support precision medicine efforts aimed at achieving better patient outcomes. The IDT Archer FUSIONPlex Core Solid Tumor Panel is a targeted next-generation sequencing assay specifically developed to identify gene fusions and mutations in solid tumors, facilitating precise oncology applications and informed treatment choices. As an example, Integrated DNA Technologies (IDT), a genomic solutions provider based in the United States, unveiled the IDT Archer FUSIONPlex Core Solid Tumor Panel in April 2023, which is an enhanced testing solution for cancer research that now provides broader and optimized coverage for single nucleotide variants (SNVs) and indels. This RNA-based sequencing assay streamlines the detection of fusions and the identification of variants in solid tumors by using just one sample input, delivering a scalable and user-friendly option to researchers that conserves time, resources, and expenses.
Minimal Residual Disease Testing Market Company Landscape And Strategic Competition
Major companies operating in the minimal residual disease testing market are Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
Access The Complete Minimal Residual Disease Testing Market Report:
Minimal Residual Disease Testing Market Regional Analysis And Leading Geography
North America was the largest region in the minimal residual disease testing market in 2025. The regions covered in the minimal residual disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
